Showing 861-870 of 3412 results for "".
How Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiDermwire TV Extra: The Global Access to Skin Health Observatory
https://practicaldermatology.com/series/dermwire-tv/global-access-skin-health-observatory/29873/Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the International Foundation of Dermatology with the International League of Dermatological Societies (ILDS), talks with Practical Dermatology about her workSkin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.Advances in Understanding the Skin’s Microbiome
https://practicaldermatology.com/series/dermatology-dispatches/advances-in-understanding-the-skins-microbiome/19772/A growing body of evidence suggests that cutaneous dysbiosis plays a role in atopic dermatitis, psoriasis, acne, and rosacea, explains Adam Friedman, MD. Efforts to encourage diversity in the skin’s microbiome with pre- and probiotics may change the way dermatologists treat these diseases in the futFDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuNew Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tCOVID-19 Impact: Interrupted EBD Regimens
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/covid-19-impact-on-interrupted-ebd-regimens/19764/Aesthetic treatments aren't considered essential at this time, but what do you do about patients who were in the middle of a series of energy-based treatments? Eric Bernstein, MD says the good news is that the skin doesn't forget. Now is a great time to focus on topical therapies that complement in-The Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.Strategies for Success: Tips on Running a Successful Dermatology Practice
https://practicaldermatology.com/conferences/scale-2023/strategies-for-success-tips-on-running-a-successful-dermatology-practice/20199/Mark D. Kaufmann, MD, Chief Medical Officer of Advanced Dermatology and Cosmetic Surgery Clinics, discusses what it takes to run a successful dermatology practice today, including the importance of leveraging data to prove value and sharpening business skills.